Effectiveness of mRNA COVID-19 Vaccination on SARS-CoV-2 Infection and COVID-19 in Sicily over an Eight-Month Period

Amodio, Emanuele; Vella, Giuseppe; Restivo, Vincenzo; Casuccio, Alessandra; Vitale, Francesco; Palermo, On Behalf Of The Covid-Surveillance Working Group Of The University Of

doi:10.3390/vaccines10030426

Cited by 10 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, a study carried out in the United Kingdom has reported a vaccine effectiveness of the booster dose of 73.9% against SARS-CoV-2 infection, consistent with our 78% [28]. However, the small variations in results between studies could be attributed to factors such as the prevalence of different COVID-19 variants, prevention strategies and population characteristics (e.g., mask-wearing was mandatory in Italy but not in the UK) [29,30]. In Israel, vaccine effectiveness against severe disease and death from COVID-19 was found to be 92% and 90%, respectively, confirming the soundness of our results against severe outcomes [31].…”

Section: Discussionsupporting

confidence: 87%

Effectiveness of mRNA Vaccine Booster against SARS-CoV-2 Infection and COVID-19 in the Adult Population during the First Three Months of the Omicron Wave in Sicily

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background: In Italy, the administration of the COVID-19 vaccine booster dose started on 27 September 2021, supported by clinical trials corroborating its efficacy. Given the paucity of real-world effectiveness data, this study aims to estimate the vaccine effectiveness of the booster dose against SARS-CoV-2 infection, severe disease, and death in the adult Sicilian population. Methods: This retrospective cohort study was carried out from 1 January to 31 March 2022 and included all residents in Sicily aged ≥ 18 years without previous SARS-CoV-2 infection and with a complete mRNA vaccine primary cycle. The cohort was split into two groups (booster and primary cycle) matched by age, gender, vaccine type, and month of completion of the primary vaccination cycle. Results: 913,382 subjects were observed in the study: 456,690 (50%) were vaccinated with two doses and 456,692 (50%) with three doses. There were 43,299 cases of SARS-CoV-2 among the two-doses vaccinees (9.5%) and 10,262 (2.2%) among the three-doses counterpart. Vaccine effectiveness in the booster cohort was 76.5% and 74.4% against SARS-CoV-2 infection, 85.7% and 79.7% against severe disease, and 84.1% and 73.1% against intubation or death, for BNT162b2 and mRNA-1273, respectively. Conclusions: This study confirmed the remarkable efficacy profile of the SARS-CoV-2 vaccine booster dose against infection, severe disease, and death attributable to the virus. Overall, the results of this study provide important real-world data to support the continued roll-out of the COVID-19 booster dose and have the potential to inform public health policy and guide decisions on vaccination strategies in countries around the world.

show abstract

Section: Discussionsupporting

confidence: 87%

Effectiveness of mRNA Vaccine Booster against SARS-CoV-2 Infection and COVID-19 in the Adult Population during the First Three Months of the Omicron Wave in Sicily

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Of the studies reporting in the UK, 14 were conducted specifically in England ( 10 , 13 , 14 , 24 , 42 , 49 , 50 , 53 ), 5 in Scotland ( 54 , 85 , 97 ), and 3 in Wales ( n = 3) ( 18 , 65 ). Other studies were in Israel ( n = 9) ( 15 , 29 , 30 , 39 – 41 , 57 , 74 , 92 ), Italy ( n = 8) ( 11 , 19 , 20 , 34 , 35 , 38 , 63 )), Brazil ( n = 6) ( 23 , 67 , 82 , 93 , 96 ), Malaysia ( n = 4) ( 44 , 76 , 77 ), Spain ( n = 4) ( 31 , 61 , 87 ), Finland ( n = 3) ( 68 , 87 ), South Africa ( n = 3) ( 67 , 82 , 98 ), Canada ( n = 3) ( 27 , 75 , 90 ), France ( n = 2) ( 62 ), Argentina ( n = 2) ( 67 , 82 ), Germany ( n = 2) ( 67 , 82 ), Qatar ( n = 2) ( 25 , 78 ), Sweden ( n = 2) ( 58 ), Hungary ( n = 2) ( 86 ), Turkey ( n = 2) ( 67 , 82 ), Kuwait ( n = 2) ( 8 ), South Korea ( n = 1) ( 47 ...…”

Section: Resultsmentioning

confidence: 99%

Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review

Reynolds,

Dewey,

Asfour

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

The purpose of this systematic review was to report on the vaccine efficacy (VE) of three SARS-CoV-2 vaccines approved by Health Canada: Pfizer BioNTech, Moderna, and AstraZeneca. Four databases were searched for primary publications on population-level VE. Ninety-two publications matched the inclusion criteria, and the extracted data were separated by vaccine type: mRNA vaccines (Pfizer and Moderna) and the AstraZeneca vaccine. The median VE for PCR-positive patients and various levels of clinical disease was determined for the first and second doses of both vaccine types against multiple SARS-CoV-2 variants. The median VE for PCR-positive infections against unidentified variants from an mRNA vaccine was 64.5 and 89%, respectively, after one or two doses. The median VE for PCR-positive infections against unidentified variants from the AstraZeneca vaccine was 53.4 and 69.6%, respectively, after one or two doses. The median VE for two doses of mRNA for asymptomatic, symptomatic, and severe infection against unidentified variants was 85.5, 93.2, and 92.2%, respectively. The median VE for two doses of AstraZeneca for asymptomatic, symptomatic, and severe infection against unidentified variants was 69.7, 71, and 90.2%, respectively. Vaccine efficacy numerically increased from the first to the second dose, increased from the first 2 weeks to the second 2 weeks post-vaccination for both doses, but decreased after 4 months from the second dose. Vaccine efficacy did not differ by person's age.

show abstract

“…Twelve reviews were excluded from the 77 studies, 21 studies lacked sufficient data, two studies were related to inactivated vaccine, 58,59 and two studies were duplicated 24,60 . Finally, 40 studies out of total 1043 abstracts were finally included in our meta‐analysis, 16–54,60 involving 62 954 861 participates and two kinds of COVID‐19 mRNA vaccines, namely BNT162b2 and mRNA‐1273; two kinds of viral vector vaccines, namely ChAdOx1 and Ad26. COV2.S.…”

Section: Resultsmentioning

confidence: 99%

Effectiveness of mRNA and viral‐vector vaccines in epidemic period led by different SARS‐CoV‐2 variants: A systematic review and meta‐analysis

Zhang

Yang

Huang

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

We assessed the effectiveness of mRNA and viral-vector vaccines in epidemic period led by different SARS-CoV-2 variants. Systematic search of PubMed, EMBASE, and CNKI (China National Knowledge Infrastructure) databases without language restriction for studies published before September 19, 2022. The review was registered with PROSPERO (CRD42022335430) and reported according to PRISMA guidelines. Forty studies met the inclusion criteria for this study, with 62 954 861 participants. The overall vaccine effectiveness (VE) to prevent COVID-19 infection was 0.76 (95% confidence interval [CI] 0.73-0.78), symptomatic infection was 0.87 (95% CI 0.83-0.91), hospital admissions was 0.82 (95% CI 0.75-0.87), and mortality was 0.76 (95% CI 0.48-0.89). Subgroup analysis were performed to characterize the effectiveness of different vaccines. When SARS-CoV-2 variants are taking account, the VE decreased along with the variation of the virus by clinical outcomes and vaccine types. The findings of this systematic review provide the best available evidence that BNT162b2, mRNA-1273, ChAdOx1, and Ad26. COV2.S seems to be approximately effective from predelta to omicron, but only modestly effective in participants aged 65 or older. When SARS-CoV-2 variants are taking account, VE decreased along with the variation of the virus for all mRNA and viral-vector vaccines.

show abstract

Effectiveness of mRNA COVID-19 Vaccination on SARS-CoV-2 Infection and COVID-19 in Sicily over an Eight-Month Period

Cited by 10 publications

References 16 publications

Effectiveness of mRNA Vaccine Booster against SARS-CoV-2 Infection and COVID-19 in the Adult Population during the First Three Months of the Omicron Wave in Sicily

Effectiveness of mRNA Vaccine Booster against SARS-CoV-2 Infection and COVID-19 in the Adult Population during the First Three Months of the Omicron Wave in Sicily

Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review

Effectiveness of mRNA and viral‐vector vaccines in epidemic period led by different SARS‐CoV‐2 variants: A systematic review and meta‐analysis

Contact Info

Product

Resources

About